cabergoline has been researched along with Chronic Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colao, A; D'Andrea, M; Di Sarno, A; Gaccione, M; Galderisi, M; Guerra, E; Lerro, G; Lombardi, G; Pardo, M; Pivonello, R | 1 |
| Díez, JJ; Iglesias, P | 1 |
2 other study(ies) available for cabergoline and Chronic Disease
| Article | Year |
|---|---|
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Chronic Disease; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency; Ultrasonography | 2008 |
Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient.
Topics: Anemia; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Chronic Disease; Dopamine Agonists; Drug Therapy, Combination; Early Detection of Cancer; Ergolines; Hematocrit; Hemoglobins; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypogonadism; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyroxine; Treatment Outcome | 2011 |